For example, the majority of patients in our study were taking hydroxychloroquine, which has been shown to impact TLR7/9 activation and reducing IFNα and TNFα production by pDCs in SLE patients (37, 38). This evidence concerns the gene IFNA2 and systemic lupus erythematosus.